İlaçların Etki Ya Da Çekilmesi İle İlişkili Baş Ağrıları
Özet
Maddelerin etki ya da çekilmesiyle ilişkili baş ağrıları, polikliniklerde sık karşılaşılan ve yüksek disabiliteye yol açan sekonder baş ağrısı bozukluklarıdır. Uluslararası Baş ağrısı Derneği (IHS) kriterlerine göre bu grup; madde kullanımına/maruziyetine bağlı baş ağrısı, ilaç aşırı kullanım baş ağrısı (İAB) ve maddenin bırakılmasına bağlı baş ağrısı olmak üzere üç alt başlıkta incelenir. Nitrik oksit, fosfodiesteraz inhibitörleri, karbonmonoksit ve alkol gibi maddeler akut veya gecikmiş baş ağrısına yol açabilir. Sekonder baş ağrıları içinde en sık rastlanan tür olan İAB, önceden primer baş ağrısı olan kişilerin en az üç ay boyunca ayda belirli günlerde ergotamin, triptan, analjezik veya opioid gibi akut atak ilaçlarını aşırı tüketmesiyle gelişir ve beyinde metabolik ile morfolojik değişikliklere neden olabilir. İAB tedavisinde ilk adım, ilaç arınması (detoksifikasyon) ve ardından relapsları önlemek için hasta bazlı profilaktik tedavilerin (beta blokerler, topiramat, onabotulinumtoxin-A vb.) uygulanmasıdır. Maddenin bırakılmasına bağlı baş ağrılarında ise kafein, opioid ve östrojen gibi maddelerin kronik kullanımının ardından kesilmesiyle 24 saat veya 5 gün içinde yoksunluk baş ağrısı gelişir. Bu bozuklukların yönetiminde etkenin doğru tanınması, hasta-hekim işbirliği ve eşlik eden psikiyatrik komorbiditelerin göz ardı edilmemesi klinik başarı açısından kritik öneme sahiptir.
Headaches associated with the effect or withdrawal of substances are secondary headache disorders commonly encountered in outpatient clinics that lead to high disability. According to the International Headache Society (IHS) criteria, this group is classified into three subcategories: headache attributed to substance use or exposure, medication-overuse headache (MOH), and headache attributed to substance withdrawal. Substances such as nitric oxide, phosphodiesterase inhibitors, carbon monoxide, and alcohol can cause acute or delayed headaches. MOH, the most frequent type among secondary headaches, develops when individuals with pre-existing primary headaches overuse acute attack medications like ergotamine, triptans, analgesics, or opioids for a certain number of days per month for at least three months, and it can cause metabolic and morphological changes in the brain. The first step in MOH treatment is drug withdrawal (detoxification), followed by patient-specific prophylactic treatments (such as beta-blockers, topiramate, onabotulinumtoxin-A, etc.) to prevent relapses. In headaches associated with substance withdrawal, abstinence from chronic use of substances like caffeine, opioids, and estrogen triggers withdrawal headaches within 24 hours or 5 days. Accurate identification of the causative agent, patient-physician cooperation, and not ignoring psychiatric comorbidities are critically important for clinical success in managing these disorders.
Referanslar
Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1–211.
Toom K, Braschinsky M, Obermann M, et al, Secondary headache attributed to exposure to or overuse of a substance, Cephalalgia. 2021 Apr;41(4):443-452. doi: 10.1177/0333102420942238
Gozalov A, Jansen-Olesen I, Klaerke D, et al. Role of BK (Ca) channels in cephalic vasodilation induced by CGRP, NO and transcranial electrical stimulation in the rat, Cephalalgia 2007; 27: 1120–1127
Strecker T, Dux M, Messlinger K, Nitric oxide releases calcitonin-gene-related peptide from rat dura mater encephali promoting increases in meningeal blood flow, J Vasc Res 2002; 39: 489–496
De Col R, Koulchitsky SV, Messlinger KB, Nitric oxide synthase inhibition lowers activity of neurons with meningeal input in the rat spinal trigeminal nucleus, Neuroreport 2003; 14: 229–232
Diener HC, Dahlöf CGH, Headache associated with chronic use of substances, The headaches, 2nd edn. Philadelphia: Lippincott, Williams & Wilkins, 1999: 871–78
Cargnin S, Viana M, Sances G, et al. A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache, Cephalalgia 2018; 38: 1361–1373
Mathew NT, Pathophysiology of chronic migraine and mode of action of preventive medications, Headache 2011; 51(Suppl 2): 84–92
Fumal A, Laureys S, Di Clemente L, et al. (2006) Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine, Brain 129:543–550
Riederer F, Marti M, Luechinger R, et al. (2012) Grey matter changes associated with medication-overuse headache: correlations with disease related disability and anxiety, World J Biol Psychiatry 13:517–525
Lai TH, Chou KH, Fuh JL, et al. Gray matter changes related to medication overuse in patients with chronic migraine, Cephalalgia. 2016 Dec;36(14):1324-1333. doi: 10.1177/0333102416630593
Schwedt TJ and Chong CD, Medication overuse headache: Pathophysiological insights from structural and functional brain MRI research, Headache 2017; 57: 1173–1178
Westergaard M, L. Hansen E, H. Glumer C, et al. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: systematic review, Cephalalgia 34, 409–425 (2014)
Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population, Cephalalgia. 2011;31:1015-1022
Straube A, Pfaffenrath V, Ladwig KH, et al. Prevalence of chronic migraine and medication overuse headache in Germany-the German DMKG headache study, Cephalalgia 2010; 30: 207–13
Diener HC, Limmroth V, Medication-overuse headache: a worldwide problem, Lancet Neurology 2004; 3: 475–83
Stark RJ, Ravishankar K, Siow HC, et al. Chronic migraine and chronic daily headache in the AsiaPacific region: A systemic review, Cephalalgia 2013; 33: 266–283
Fuh JL and Wang SJ. Dependent behavior in patients with medication-overuse headache, Curr Pain Headache Rep 2012; 16: 73–79
Biagianti B, Grazzi L, Gambini O, et al. Orbitofrontal dysfunction and medication overuse in patients with migraine, Headache 2012; 52: 1511–1519
Go´mez-Beldarrain M, Carrasco M, Bilbao A, et al. Orbitofrontal dysfunction predicts poor prognosis in chronic migraine with medication overuse, J Headache Pain 2011; 12: 459–466
Chiang CC, Schwedt TJ, Wang SJ, et al. Treatment of medication-overuse headache: a systematic review, Cephalalgia 2015
Radat F, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache, Cephalalgia 25, 519–522 (2005)
Diener HC, Holle D, Dresler T, et al. Chronic Headache Due to Overuse of Analgesics and Anti-Migraine Agents, Dtsch Arztebl Int. 2018 Jun 1;115(22):365-370, doi: 10.3238/arztebl.2018.0365
Kendir Ae, Beckmann Y, Seçil Y, et al, The Clinical and Treatment Characteristics of Medication Overuse Headache, Turkiye Klinikleri J Neurol-Special Topics 2018;11(1):84-8
Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate fort he treatment of chronic migraine. A randomized, double-blind, placebo controlled trial, Headache 2007;47: 170-80
Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine. A randomides double blind placebo controlled phase 2 trial. Lancet Neurol 2017;16:425-34
Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine, N Engl J Med 2017; 377: 2113–22
Rabe K, Pageler L, Gaul C, et al.Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia 2013; 33:202-207
Aurora SK, Dodick DW, Turkel CC, et al. Onabotuli- numtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial, Cephalalgia 2010; 30: 793–803
Tassorelli C, Jensen R, Allena M, et al, the COMOESTAS Consortium. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia. 2014 Aug;34(9):645-655
Saper JR, Da Silva AN. Medication overuse headache: history, features, prevention and management strategies. CNS Drugs. 2013 Nov;27(11):867-77
Alstadhaug KB, Andreou AP. Caffeine and primary (migraine) headaches, Front Neurol. 2019;10:1275
